Orleans Cedex 2

• ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of … Recruiting
  2024-517099-39-00 4 2024-11-18 Newly diagnosed transplant ineligible multiple myeloma
• Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting
  2024-516394-78-00 5 2024-11-05 Patient with sepsis complicated by ARDS
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting
  2023-504670-38-00 4 2023-11-17 Extensive disease Small Cell Lung Cancer
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
• Apneic oxygenation with high-flow nasal oxygenation after preoxygenation with noninvasive ventilation before intubation in hypoxemic patient … Recruiting
  2024-514949-11-00 5 2026-03-18 Hypoxemic acute respiratory failure
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the … Recruiting
  2023-508861-34-00 9 2025-12-02 Pneumocystis pneumonia
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe … Recruiting
  2023-506843-40-00 5 2025-10-29 Mycobacterium xenopi pulmonary infection
• Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting
  2024-511871-13-00 6 2025-10-02 Postmenopausal osteoporosis
• Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial … Recruiting
  2023-510099-30-00 5 2025-09-23 Out-of-hospital cardiac arrest with initial shockable rhythm
• A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting
  2024-519291-11-00 4 2025-07-25 Psoriatic Arthritis
• Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting
  2024-515787-31-00 5 2025-07-18 Patient with early triple-negative breast cancer (TNBC) achieving path
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial Recruiting
  2024-516780-93-00 5 2025-07-09 Sustained immunosuppression
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 6 2025-06-16 Rheumatoid arthritis
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis

Showing 25–48 of 136 trials